This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): MLN0518, MLN518, CT53518
Description: MLN0518 inhibits Flt-3 and platelet-derived growth factor (PDGF) receptor tyrosine kinases (RTK). Approximately 30% of AML patients have a mutation of their Flt-3 gene which may be implicated in the growth and survival of this leukemia. In preclinical studies, MLN518 selectively killed human Flt-3 mutant AML leukemia cells.
Deal Structure: MLN0518 was originally developed by Millennium.
In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The acquisition closed in May 2008.
Additional information available to subscribers only: